Table 5.
Daily and cumulative doses and administration periods of DPP4 inhibitors and lisinopril in the propensity score-matched cohorts.
| Without lisinopril | With lisinopril | |||||
|---|---|---|---|---|---|---|
| DPP4 inhibitor | DPP4 inhibitor | Lisinopril | ||||
| Median(IQR) | Range | Median(IQR) | Range | Median(IQR) | Range | |
| Average daily dose (DDD*) | 1 (1–1) |
0.001 –1000 |
1 (1–1) |
0.005 –1000 |
1.5 (0.86–2) |
0.05 –2000 |
| Cumulative dose (DDD*) | 180 (90–360) |
0.12 – 630000 |
180 (90–390) |
0.15 –390000 |
360 (125–810) |
1 –720000 |
| Administration period (day) | 180 (90–390) |
1 –1440 |
210 (90–420) |
1 –1515 |
270 (120–450) |
1 –1,740 |
The median value, interquartile range (IQR), and minimum-maximum ranges are shown for each group. Each dose is shown as a ratio to the defined daily dose (DDD). *DDD: 100 mg sitagliptin, 5 mg saxagliptin, 25 mg alogliptin, 5 mg linagliptin, or 10 mg lisinopril was considered as 1.